| Page 29 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Author(s): 
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS
Primary Author: 
Platzbecker U
Journal Title: 
Lancet
Original Publication Date: 
Jan 2024

Background: Unmet medical needs remain in patients with

Bone Marrow Disease(s): 

T cell dysfunctions in myelodysplastic syndromes

Author(s): 
Rodriguez-Sevilla JJ, Colla S
Primary Author: 
Rodriguez-Sevilla JJ
Journal Title: 
Blood
Original Publication Date: 
Jan 2023

Escape from immune surveillance is a hallmark of cancer. Immune deregulation caused by intrinsic and extrinsic cellular factors, such as altered T cell functions, leads to immune exhaustion, loss of immune surveillance, and clonal proliferation of tumoral cells. The T cell immune system contributes to the pathogenesis, maintenance, and progression of myelodysplastic syndrome (MDS).

Bone Marrow Disease(s): 

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes

Author(s): 
DeZern AE, Greenberg PL
Primary Author: 
Dezern AE
Journal Title: 
Blood
Original Publication Date: 
Dec 2023

Risk stratification and prognostication are crucial for the appropriate management of patients with

Bone Marrow Disease(s): 

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53

Author(s): 
Siddon AJ, Weinberg OK
Primary Author: 
Siddon AJ
Journal Title: 
Clinics in Laboratory Medicine
Original Publication Date: 
Dec 2023

The genetic underpinnings of myeloid neoplasms are becoming increasingly well understood. The accessibility to sequencing technology, in particular next-generation sequencing (NGS), has highlighted the importance of gene mutations in

Bone Marrow Disease(s):